Results 181 to 190 of about 25,638 (254)

Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy. [PDF]

open access: yesPediatr Obes
Tran BC   +14 more
europepmc   +1 more source

Global Landscape and Thematic Evolution of Selective GLP‐1 Receptor Agonists and GLP‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang   +6 more
wiley   +1 more source

A clinical and experimental investigation of liraglutide effects on the brain-kidney axis. [PDF]

open access: yesSci Adv
Greenwood MP   +6 more
europepmc   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9966-9979, November 2026.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble   +7 more
wiley   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9941-9954, November 2026.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo   +3 more
wiley   +1 more source

GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework. [PDF]

open access: yesJ Clin Med
Kaltsas A   +6 more
europepmc   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9849-9860, November 2026.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy